全文获取类型
收费全文 | 169022篇 |
免费 | 11609篇 |
国内免费 | 1281篇 |
专业分类
耳鼻咽喉 | 2321篇 |
儿科学 | 3321篇 |
妇产科学 | 4004篇 |
基础医学 | 24804篇 |
口腔科学 | 3511篇 |
临床医学 | 16004篇 |
内科学 | 32089篇 |
皮肤病学 | 4443篇 |
神经病学 | 12725篇 |
特种医学 | 8439篇 |
外科学 | 23434篇 |
综合类 | 2344篇 |
现状与发展 | 5篇 |
一般理论 | 88篇 |
预防医学 | 10072篇 |
眼科学 | 5146篇 |
药学 | 14284篇 |
中国医学 | 1648篇 |
肿瘤学 | 13230篇 |
出版年
2023年 | 865篇 |
2022年 | 666篇 |
2021年 | 4318篇 |
2020年 | 2679篇 |
2019年 | 3868篇 |
2018年 | 4729篇 |
2017年 | 3467篇 |
2016年 | 4416篇 |
2015年 | 5901篇 |
2014年 | 7265篇 |
2013年 | 8808篇 |
2012年 | 13329篇 |
2011年 | 13013篇 |
2010年 | 7689篇 |
2009年 | 6462篇 |
2008年 | 9907篇 |
2007年 | 9836篇 |
2006年 | 9089篇 |
2005年 | 8679篇 |
2004年 | 7726篇 |
2003年 | 6733篇 |
2002年 | 5861篇 |
2001年 | 4788篇 |
2000年 | 4383篇 |
1999年 | 3517篇 |
1998年 | 1307篇 |
1997年 | 958篇 |
1996年 | 929篇 |
1995年 | 927篇 |
1994年 | 808篇 |
1993年 | 701篇 |
1992年 | 1737篇 |
1991年 | 1742篇 |
1990年 | 1498篇 |
1989年 | 1347篇 |
1988年 | 1279篇 |
1987年 | 1170篇 |
1986年 | 1111篇 |
1985年 | 977篇 |
1984年 | 701篇 |
1983年 | 631篇 |
1982年 | 444篇 |
1981年 | 417篇 |
1980年 | 375篇 |
1979年 | 583篇 |
1978年 | 450篇 |
1977年 | 407篇 |
1976年 | 354篇 |
1974年 | 366篇 |
1973年 | 342篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
3.
4.
Lee Hee Yun Hao Zhichao Choi Eun Young 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(4):996-1004
Journal of Immigrant and Minority Health - Little attention has been paid to online health information seeking (OHIS) among immigrants residing in rural areas. This study examines the intensity of... 相似文献
5.
6.
7.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
8.
Tran Thi Hien Ines Ambite Murphy Lam Yim Wan Michele Cavalera Parisa Esmaeili Arunima Chaudhuri Samudra Sabari Marek Babjuk Catharina Svanborg 《International journal of cancer. Journal international du cancer》2023,153(3):584-599
Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer. 相似文献
9.
Su Chien-Chia Lee Yi-Chieh Lee Peter Richmond Candano 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2397-2397
Graefe's Archive for Clinical and Experimental Ophthalmology - 相似文献
10.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097